share_log

HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $11 Price Target

Benzinga ·  Nov 15, 2023 06:53

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $11 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment